Immediate Adverse Effects of Peptide Receptor Radionuclide Therapy (PRRT) Administration in Patients with Neuroendocrine Tumors (NETs): A Single Institution Review

#2744

Introduction: PRRT is an effective treatment for well-differentiated NET, but immediate adverse events during or shortly after administration of the treatment are not well defined.

Aim(s): To explore the frequency of and characterize early adverse events following PRRT in a real-world patient cohort.

Materials and methods: We reviewed patients at Mayo Clinic who had started treatment with PRRT (Lu-177 Dotatate) as of December 2018. Baseline patient demographics including oncology history were collected. Primary outcome was the presence of any symptoms during treatment. Secondary outcomes included emergency department (ED) visits or hospitalizations within 30 days following a PRRT cycle.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Wee C, Dundar A, Packard A, Kendi A, Eiring R,

Keywords: prrt, peptide receptor radionuclide therapy,